NLS-101 Phase II clinical trial starts
The primary objective of the trial is to investigate the analgesic efficacy of a topically applied dose of NSL-101 prior to the procedure, compared to the application of the standard lidocaine gel. The secondary objectives are to ascertain NSL-101's anti-inflammatory action and safety compared to the conventional gel. Subject to recruitment, it is anticipated that the trial will finish in Q1 2008 and that results will be made available in Q2 2008.
NeuroSolutions has collaborated with Ampika Ltd to develop further knowledge of Peruvian medicinal plants with a view to capitalising on opportunities offered by herbal formulations. NSL-101 was identified from the Ampika database of medicinal plants as a natural product formulation that is effective in alleviating the symptoms of dental pain. The product has been used in documented, empirical form for more than 5 centuries as a dental analgesic in Peru, with anti-inflammatory and disinfectant effects, in chewed form, with or without other meals. The detailed studies of its electrophysiology demonstrate that a preparation of NSL-101 inhibits the discharges of the damaged nerves associated with pain. NeuroSolutions owns NSL-101 via a worldwide exclusive license.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.